KROS

Rating buyAI Memo

Keros Therapeutics

As of 2025-11-13/Confidence medium/Horizon 3m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2025-11-13 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

medium

Horizon

Key catalyst

Clinical readout for lead hematology program (mid-stage)

Expected move: +74%

Biggest risk

Clinical failure, regulatory delay, or short cash runway could compress valuation toward the low-teens or below, driven by binary outcomes and near-term dilution.

Invalidation

Break below $13 or thesis failure.

What would change my mind?

Positive mid-stage clinical data and a partnership would materially de-risk the franchise, supporting >30% upside to the anchor within a few quarters.

Research note

Recommendation

buy

Confidence

medium

As of

2025-11-13

Base target

$19

p=60%

Bull target

$24

p=20%

Bear target

$13

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Quarterly operating update / cash runway disclosure
Partnership or licensing deal for commercial/late-stage development
Positive mid-stage clinical data and a partnership would materially de-risk the franchise, supporting >30% upside to the anchor within a few quarters.

BearKey bullets

Clinical failure, regulatory delay, or short cash runway could compress valuation toward the low-teens or below, driven by binary outcomes and near-term dilution.

WatchKey bullets

Clinical readout for lead hematology program (mid-stage)

Summary

High-level snapshot

Recommendation

buy

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $19 (p=60%)

Bull/Bear spread: +114% / +19%

Vs latest close: Bull +114% · Base +74% · Bear +19%

Scenario probabilities

Bull Target: $24 (p=20%)Base Target: $19 (p=60%)Bear Target: $13 (p=20%)

Commentary

Market tone is cautiously constructive around clinical milestones but sensitive to binary readouts; recent anchor price reflects rapprochement after earlier volatility [#ANCHOR]. Short-term sentiment is driven by funding and readout timelines, while longer-term views hinge on data and partnering prospects [#ANCHOR].

As of 2025-11-13 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Positive mid-stage clinical data and a partnership would materially de-risk the franchise, supporting >30% upside to the anchor within a few quarters.

Bear Case

Clinical failure, regulatory delay, or short cash runway could compress valuation toward the low-teens or below, driven by binary outcomes and near-term dilution.

Drivers

Scannable catalysts and supporting factors

Quarterly operating update / cash runway disclosure
Partnership or licensing deal for commercial/late-stage development

Scenarios

Bull Target (Scenario probability)

$24 / p=20% prob

Base Target (Scenario probability)

$19 / p=60% prob

Bear Target (Scenario probability)

$13 / p=20% prob

Price $11 as of 2026-07-15

Nearest Scenario: Bear (∆ 19%)

Targets vs latest close: Bull +114% · Base +74% · Bear +19%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT
Clinical readout for lead hematology program (mid-stage)
Mid-stage efficacy/safety readout could re-rate the stock materially if positive; downside risk on negative results [#ANCHOR].
Prob 45.00% • Move 35.00% • Priced-in 30.00%

Short-term Catalysts

Next few weeks

Quarterly operating update / cash runway disclosure
TBD
Balance-sheet updates or guidance could produce near-term volatility and downside if runway is shorter than expected [#ANCHOR].
Prob 80% • Move 12% • Priced-in 50%

Long-term Catalysts

Months to a year

Partnership or licensing deal for commercial/late-stage development
TBD
A strategic BD/partnering deal would de-risk development capital needs and likely drive multi-quarter upside [#ANCHOR].
Prob 25% • Move 25% • Priced-in 20%

Risks

No risks

Peers

Symbol	Summary
CRSP	Clinical-stage biotech with multiple programs; similar risk profile for development-stage catalysts.
SGMO	Gene/rare-disease biotech—comparable binary readout risk and capital intensity.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Analysis date: 2025-11-13

AI Stock Memo: KROS - Keros Therapeutics - RankAlpha